Filing Flows › Atara Biotherapeutics (ATRA) › Q1 2026
Atara Biotherapeutics (ATRA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 12, 2026
Atara Biotherapeutics (ATRA) reported revenue of $516K for the first quarter 2026 (Q1 2026), -99% from a year earlier and -68% from the quarter before. Operating margin was -652.9%, net loss $4.1M (803.3% of revenue).
Atara Biotherapeutics, Q1 2026: revenue $516K (-100% year over year), operating margin -652.9%, net loss $4.1M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $516K | -68% | -99% |
| Operating profit | −$3.4M | — | -109% |
| Net earnings | −$4.1M | — | -111% |
| Operating cash flow | −$3.1M | — | — |
What changed
Revenue was $516K in Q1 2026, down 99% year over year and down 68% from the previous quarter.
Operating costs exceeded revenue by $3.4M, an operating margin of -652.9%. Total costs fell 93% while revenue fell 99%. The quarter ended with a net loss of $4.1M, wider than the previous quarter's $3.4M loss.
Operating cash flow was −$3.1M. Non-cash charges added back $29K of depreciation and amortization and $749K of share-based compensation. Working capital and other items added $294K.
Questions
What was Atara Biotherapeutics' revenue in the first quarter 2026?
Atara Biotherapeutics (ATRA) reported revenue of $516K for the first quarter 2026 (Q1 2026), -99% from a year earlier and -68% from the quarter before.
Was Atara Biotherapeutics profitable in the first quarter 2026?
Operating loss was $3.4M (-652.9% of revenue) and net loss $4.1M.